Search | Clinical Trials Finder

Conditions: Vascular Diseases
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Fontan Circulation
Interventions: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Heart Failure With Reactive Pulmonary Hypertension
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Maya Guglin; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions: Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Congestive Heart Failure, Renal Dysfunction
Interventions: low dose Nesiritide, nesiritide, Sildenafil; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Rochester, Minnesota

Conditions: Female Sexual Arousal Disorder
Interventions: Sildenafil 100 mg, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Erectile Dysfunction
Interventions: tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)]; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Huntsville, Alabama • Newport Beach, California • Middlebury, Connecticut + 4 more

Conditions: Diabetic Neuropathy
Interventions: sildenafil (Viagra); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Emphysema
Interventions: Sildenafil; Drug
Lead sponsor: Eric A. Hoffman; Other
Eligibility: 25 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Nephrogenic Diabetes Insipidus
Interventions: sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 25 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island

Conditions: Benign Prostatic Hyperplasia
Interventions: placebo, sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Laguna Woods, California • Newport Beach, California

Conditions: Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions: Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 1 Year to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Emphysema
Interventions: Sildenafil study group; Drug
Lead sponsor: Eric A. Hoffman; Other
Eligibility: 30 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: 5% Sildenafil Cream (SST-6006), Oral Sildenafil 50 mg; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypogonadism, Erectile Dysfunction
Interventions: Testim®, Placebo Testim®, Viagra®; Drug · Other
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatitis
Interventions: Viagra (sildenafil citrate); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Heart Failure
Interventions: Placebo, Sildenafil; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 6 more

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI; Drug · Device · Other + 1 more
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg, Leu Met Sil 4.0mg, Placebo; Drug
Lead sponsor: NuSirt Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 15
States / cities: Mobile, Alabama • Montclair, California • Sacramento, California + 12 more

Conditions: Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions: Sildenafil Citrate, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate low dose, Placebo, Sildenafil medium dose, Sildenafil high dose; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Erectile Dysfunction
Interventions: Sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Treatment of Supine Hypertension in Autonomic Failure

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Hypoxic Pulmonary Vasoconstriction Pilot Study

Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults

Testosterone for Penile Rehabilitation After Radical Prostatectomy

Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III

Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

Sildenafil for Microvasculopathy in Chronic TBI

Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.